Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 04 2021
Historique:
received: 26 10 2020
accepted: 19 03 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 10 11 2021
Statut: epublish

Résumé

The standard treatment for advanced ovarian cancer (AOC) is cytoreduction surgery and adjuvant chemotherapy. Tumor volume after surgery is a major prognostic factor for these patients. The ability to perform complete cytoreduction depends on the extent of disease and the skills of the surgical team. Several predictive models have been proposed to evaluate the possibility of performing complete cytoreductive surgery (CCS). External validation of the prognostic value of three predictive models (Fagotti index and the R3 and R4 models) for predicting suboptimal cytoreductive surgery (SCS) in AOC was performed in this study. The scores of the 3 models were evaluated in one hundred and three consecutive patients diagnosed with AOC treated in a tertiary hospital were evaluated. Clinicopathological features were collected prospectively and analyzed retrospectively. The performance of the three models was evaluated, and calibration and discrimination were analyzed. The calibration of the Fagotti, R3 and R4 models showed odds ratios of obtaining SCSs of 1.5, 2.4 and 2.4, respectively, indicating good calibration. The discrimination of the Fagotti, R3 and R4 models showed an area under the ROC curve of 83%, 70% and 81%, respectively. The negative predictive values of the three models were higher than the positive predictive values for SCS. The three models were able to predict suboptimal cytoreductive surgery for advanced ovarian cancer, but they were more reliable for predicting CCS. The R4 model discriminated better because it includes the laparotomic evaluation of the peritoneal carcinomatosis index.

Identifiants

pubmed: 33854085
doi: 10.1038/s41598-021-86928-2
pii: 10.1038/s41598-021-86928-2
pmc: PMC8047030
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8111

Investigateurs

L Gomez-Quiles (L)
R Játiva (R)
G Cebrian (G)
V Bosso (V)
A Villarin (A)
K Maiocchi (K)
K Delgado-Barriga (K)
M Rodrigo-Aliaga (M)
N Ruiz (N)
C Herrero (C)
A Frances (A)
I Beato (I)
C Ferrer (C)
J P Aracil (JP)
E Boldo (E)
A Boldo (A)
R Adell (R)

Références

Gynecol Oncol. 2006 Nov;103(2):559-64
pubmed: 16714056
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:35-40
pubmed: 16515565
Cancer. 2000 Oct 1;89(7):1532-40
pubmed: 11013368
J Gynecol Oncol. 2018 Sep;29(5):e65
pubmed: 30022629
Ann Surg. 1995 Feb;221(2):124-32
pubmed: 7857141
Int J Gynecol Cancer. 2018 Jun;28(5):1054-1055
pubmed: 29664844
Gynecol Oncol. 2017 Mar;144(3):468-473
pubmed: 28117100
Onco Targets Ther. 2018 May 15;11:2771-2777
pubmed: 29844678
Am J Obstet Gynecol. 2010 Feb;202(2):178.e1-178.e10
pubmed: 20113693
J Clin Oncol. 2007 Feb 1;25(4):384-9
pubmed: 17264334
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80
pubmed: 8166218
Gynecol Oncol. 2008 Sep;110(3):354-9
pubmed: 18572226
Cancer. 2004 Jul 15;101(2):346-52
pubmed: 15241833
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
World J Surg Oncol. 2018 Feb 23;16(1):37
pubmed: 29471831
Gynecol Oncol. 2016 Nov;143(2):264-269
pubmed: 27586894
Gynecol Oncol. 2017 Apr;145(1):27-31
pubmed: 28209497
Gynecol Oncol. 2006 Dec;103(3):1083-90
pubmed: 16890277
J Gynecol Oncol. 2020 Jan;31(1):e26
pubmed: 31789002
Ann Surg Oncol. 2006 Aug;13(8):1156-61
pubmed: 16791447
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Gynecol Oncol. 2017 Oct;147(1):104-109
pubmed: 28734497
Int J Womens Health. 2019 May 28;11:333-342
pubmed: 31239786
Eur J Surg Oncol. 2018 Jan;44(1):163-169
pubmed: 29198495
Gynecol Oncol. 2003 Aug;90(2):390-6
pubmed: 12893206
Ann Surg Oncol. 2012 Dec;19(13):4059-67
pubmed: 22766983
Arch Gynecol Obstet. 2013 Apr;287(4):733-41
pubmed: 23341061
Obstet Gynecol. 2006 Jan;107(1):77-85
pubmed: 16394043
Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92
pubmed: 21944035

Auteurs

Antoni Llueca (A)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Av Benicasim s/n, 12004, Castellón, Spain. antonillueca@gmail.com.
Department of Medicine, University Jaume I (UJI), Castellón, Spain. antonillueca@gmail.com.

María Teresa Climent (MT)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Av Benicasim s/n, 12004, Castellón, Spain.
Department of Medicine, University Jaume I (UJI), Castellón, Spain.

Javier Escrig (J)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Av Benicasim s/n, 12004, Castellón, Spain.
Department of Medicine, University Jaume I (UJI), Castellón, Spain.

Paula Carrasco (P)

Department of Medicine, University Jaume I (UJI), Castellón, Spain.

Anna Serra (A)

Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellon, Av Benicasim s/n, 12004, Castellón, Spain.
Department of Medicine, University Jaume I (UJI), Castellón, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH